ASCO 2026 opened today at McCormick Place in Chicago. More than 40,000 attendees. More than 7,000 abstracts. The energy across the conference is focused squarely on tomorrow’s plenary session—the single most anticipated event on the 2026 oncology calendar. Revolution Medicines will present full Phase 3 RASolute 302 data in second-line pancreatic cancer. Akeso will present overall survival data for ivonescimab in squamous NSCLC. J&J will present Erleada PROTEUS data in high-risk prostate cancer. We will cover the plenary data in Monday’s email. Beyond the conference, two stories illustrate the breadth of activity across life sciences today. Lantheus Holdings is weighing a take-private offer from PE-backed Curium Pharma that values the radiopharmaceutical company at approximately $7 billion—a transaction that would validate radiopharmaceuticals as a standalone investment thesis and represent one of the largest deals in the sector’s history. AbbVie received FDA approval for Decnupaz in a rare blood cancer. And BridgeBio received Priority Review for the first potential treatment for limb-girdle muscular dystrophy. The regulatory machinery continues to produce results even as ASCO dominates the headlines.
Tomorrow’s Plenary: The Three Presentations That Could Reshape Oncology
The Saturday May 31 plenary session features three datasets that each carry the potential to establish a new standard of care in their respective indications. This is the most data-dense plenary session at ASCO in years.
Revolution Medicines RASolute 302: The Pancreatic Cancer Moment
Brian Wolpin, MD (Dana-Farber) will present full Phase 3 data for daraxonrasib in second-line pancreatic ductal adenocarcinoma. We know the topline: 13.2 months median overall survival versus 6.7 months (HR 0.40, p<0.0001)—a near-doubling of survival in a disease where second-line treatment has historically offered months, not years.
What the plenary must add: PFS data (not yet disclosed), subgroup analyses across RAS mutation variants, mature survival curves showing whether the benefit is sustained over time, and detailed safety data.
The PFS data is particularly important. Overall survival is the gold standard endpoint, but PFS demonstrates that the drug delays disease progression—not just that patients live longer, but that their cancers take longer to grow. A strong PFS result alongside the OS data would provide the most complete picture of daraxonrasib’s clinical benefit and give oncologists the confidence to adopt the drug as a new standard of care.
Subgroup analyses will reveal whether the benefit is broadly distributed across patient characteristics or concentrated in specific populations. If the survival advantage holds across different RAS mutation subtypes, age groups, and performance status levels, the label could be broad. If the benefit is driven primarily by one mutation subtype or one patient demographic, the label and the addressable market narrow accordingly.
The mature survival curves will show whether the separation between the treatment and control arms is sustained over longer follow-up. The topline data came from the first interim analysis. Sustained curve separation is the strongest possible validation that the drug provides a durable benefit rather than a temporary delay in disease progression.
The stakes extend beyond the data itself. Truist projects a Q3 2026 approval under the CNPV program. If Revolution files shortly after or concurrently with the plenary, the 50-day Foundayo precedent could produce an approval by August or September. The plenary presentation is both a scientific event and a commercial inflection point—the data that drops tomorrow morning will determine whether daraxonrasib launches this year or waits until 2027.
For pancreatic cancer patients, the personal stakes are as high as the commercial ones. Pancreatic cancer has a five-year survival rate below 15%. A drug that doubles overall survival in the second line would be the most significant advance against this disease in its history. The oncology community knows this. The auditorium will be full.
Akeso Ivonescimab HARMONi-6 OS: The Keytruda Challenge
Overall survival data for ivonescimab, a PD-1/VEGF bispecific antibody developed by China’s Akeso, in squamous NSCLC. Ivonescimab previously showed a 40% PFS improvement over tislelizumab plus chemo in HARMONi-6, and separately beat Keytruda in PFS in HARMONi-02.
PFS improvements do not always translate to overall survival benefits—a lesson the oncology field has learned repeatedly. If ivonescimab demonstrates a statistically significant OS improvement in squamous NSCLC, it would be the first bispecific antibody to show survival superiority in lung cancer and the first Chinese-developed immuno-oncology agent to directly challenge the Keytruda standard of care on the endpoint that matters most to patients and regulators. The implications for Merck, for the IO competitive landscape, and for the global positioning of Chinese-developed oncology assets would be substantial.
If the OS data are negative or inconclusive—PFS improvement without OS benefit—the result would reinforce the existing IO hierarchy with Keytruda at the top and raise questions about whether PFS alone is sufficient to justify adoption of bispecific approaches in lung cancer. The oncology field has seen several examples of drugs that improved PFS without translating to OS benefit, and each case has reinforced the importance of OS as the definitive endpoint for practice change.
The broader significance of the ivonescimab data extends beyond the individual drug. If a PD-1/VEGF bispecific can demonstrate OS superiority over standard checkpoint inhibitor therapy, it would validate an entirely new therapeutic class in immuno-oncology. Bispecific antibodies that simultaneously block two pathways—immune checkpoint and angiogenesis—could become the next generation of IO therapy, potentially displacing the checkpoint inhibitor monotherapy paradigm that has dominated lung cancer treatment for a decade. The data tomorrow will determine whether that paradigm shift is beginning.
J&J Erleada PROTEUS: Opening the Plenary
Data for Erleada (apalutamide) in high-risk localized or locally advanced prostate cancer, described by pharmaphorum as a potential “paradigm shift.” Erleada is already approved in metastatic and non-metastatic castration-resistant prostate cancer. PROTEUS evaluates adding apalutamide before and after surgery in patients with high-risk disease.
Moving a prostate cancer therapy into the perioperative setting—treating around the time of surgery to prevent recurrence—follows the same trajectory that has expanded ADCs and checkpoint inhibitors from late-line to front-line treatment throughout 2026. Prostate cancer is the most common cancer in men. High-risk localized disease represents a patient population that is substantially larger than the metastatic populations where Erleada is currently approved. A positive result would expand the franchise and reinforce the industry trend of treatments moving earlier in the disease course. PROTEUS opens the plenary, setting the tone for the most consequential day of the conference.
Lantheus Weighs $7B Take-Private Offer from Curium Pharma
What Happened: Bloomberg reported that Lantheus Holdings is weighing a potential sale after receiving a take-private offer from Curium Pharma, a PE-backed radiopharmaceutical company, that values Lantheus at approximately $7 billion.
Why This Matters for the Radiopharmaceutical Sector
Lantheus is a leading radiopharmaceutical diagnostics company, best known for PyL (PSMA PET imaging for prostate cancer) and DEFINITY (cardiac perfusion imaging). The company sits at the intersection of nuclear medicine and precision oncology—two of the fastest-growing segments in the life sciences industry.
The radiopharmaceutical sector has been building momentum throughout 2026. Novartis’s Pluvicto (radioligand therapy for prostate cancer) grew 70% in Q1, validating the commercial potential of therapeutic radiopharmaceuticals. Multiple radioligand therapy programs are in clinical development across prostate cancer, breast cancer, lung cancer, and neuroendocrine tumors. The diagnostic side of the market—PSMA PET imaging in particular—has become standard of care for prostate cancer staging, creating a diagnostic-to-therapeutic pathway where the same molecular target is used first to identify patients and then to treat them.
A take-private at $7 billion would be one of the largest radiopharmaceutical transactions in history. Curium, which operates a global radiopharmaceutical manufacturing and distribution network, would gain Lantheus’s diagnostic franchise and commercial infrastructure. The combination would create the largest independent radiopharmaceutical company in the world, with capabilities spanning manufacturing, diagnostics, and a platform for therapeutic development.
For the broader industry, the Curium offer signals that private equity capital views radiopharmaceuticals as an undervalued asset class with significant growth potential. PE firms typically invest in sectors where they see operational improvement opportunities, market consolidation potential, and durable revenue growth. A $7 billion bet on radiopharmaceuticals reflects all three convictions: the manufacturing and distribution network can be optimized, the fragmented market can be consolidated, and the clinical pipeline (both diagnostic and therapeutic) provides a long runway of growth.
The timing is notable. The radiopharmaceutical sector has matured from a niche nuclear medicine subsegment into a mainstream oncology platform in just a few years. Novartis’s Pluvicto demonstrated that radioligand therapies can generate billions in revenue. PSMA PET imaging has become standard of care for prostate cancer staging. Multiple programs are in development across additional tumor types. The sector is at an inflection point where clinical validation has been established, commercial infrastructure exists, and the growth trajectory is clear—exactly the conditions that attract large-scale PE investment.
Our Pro brief analyzes why Curium’s $7B Lantheus offer signals PE capital entering nuclear medicine at scale, how the diagnostic-therapeutic integration model creates competitive advantages, and what the deal would mean for the radiopharmaceutical competitive landscape. [Details below.]
AbbVie’s Decnupaz Approved for Rare Blood Cancer
What Happened: The FDA approved AbbVie’s Decnupaz (pivekimab sunirine) on May 28 for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer with very limited treatment options. This is the second FDA-approved treatment for BPDCN.
Why This Matters: BPDCN is among the rarest and most aggressive hematologic malignancies, with median survival measured in months. The condition is so rare that it was only formally classified as a distinct disease entity in 2008. Having a second approved treatment option—the first being Elzonris (tagraxofusp)—gives physicians more flexibility in managing a disease that has historically had almost no targeted therapies. AbbVie’s hematology portfolio continues to expand alongside its immunology franchise (Skyrizi, Rinvoq) and its emerging oncology pipeline (Kestrel KRAS option deal). For AbbVie, each new approval adds a brick to the foundation the company is building to sustain growth beyond the Humira transition.
BridgeBio Gets Priority Review for First Potential LGMD Treatment
What Happened: BridgeBio Pharma announced that the FDA accepted its NDA with Priority Review for oral BBP-418 (ribitol) for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare progressive muscle-wasting disease caused by mutations in the FKRP gene.
Why This Matters: If approved, BBP-418 would be the first FDA-approved treatment for any form of limb-girdle muscular dystrophy. LGMD encompasses more than 30 genetic subtypes, all characterized by progressive weakness and wasting of the muscles closest to the body—the hips, shoulders, upper arms, and thighs. The R9 subtype (caused by FKRP mutations) is one of the more common forms. There are currently no approved therapies for any LGMD subtype, making this a genuine first-in-disease approval opportunity.
The mechanism is distinctive. Ribitol is a sugar alcohol that serves as a substrate for the glycosylation pathway affected by FKRP mutations. By providing exogenous ribitol, BBP-418 aims to restore the glycosylation of alpha-dystroglycan, a protein essential for muscle fiber stability and function. The approach addresses the molecular root cause of the disease rather than treating symptoms.
BridgeBio has been building a rare disease portfolio alongside its cardiovascular franchise (Attruby for ATTR-CM, which showed a survival signal versus Pfizer’s tafamidis in indirect comparisons earlier this month). The Priority Review designation typically yields a six-month review cycle, putting the PDUFA date in late 2026 or early 2027. For a company that began as a rare disease platform and has since expanded into cardiovascular medicine, a first-in-disease LGMD approval would reinforce the founding thesis while adding a franchise with no competitive alternatives.
Strategic Themes
1. Tomorrow Morning Is the Single Most Important Hour on the 2026 Oncology Calendar
Three plenary presentations. Three potential practice-changing datasets. Revolution in pancreatic cancer. Akeso in lung cancer. J&J in prostate cancer. The combined impact of three pivotal datasets in a single plenary session has no recent precedent at ASCO. The market’s reaction—analyst revisions, stock movements, M&A discussions, clinical practice shifts—will begin Saturday afternoon and play out through the rest of the year. We will cover the full plenary results in Monday’s email.
2. $7B in PE Capital Chasing Radiopharmaceuticals Validates the Sector
Private equity entering radiopharmaceuticals at the $7 billion level is a validation signal. PE firms invest based on commercial fundamentals, not scientific enthusiasm. A $7 billion offer for Lantheus reflects a conviction that the radiopharmaceutical market—spanning diagnostics, therapeutic radioligands, and the manufacturing infrastructure that supports both—has durable, scalable commercial potential. The Novartis Pluvicto growth data (+70% Q1) provides the clinical and commercial validation. The Curium offer converts that validation into a capital commitment.
3. Rare Disease Approvals and Filings Continue at Pace Despite the FDA Leadership Vacuum
AbbVie’s Decnupaz approval for BPDCN and BridgeBio’s Priority Review acceptance for LGMD demonstrate that the FDA’s review machinery continues to function despite the leadership disruptions at the commissioner and CDER/CBER director levels. Career review staff are processing applications, meeting PDUFA timelines, and granting appropriate designations. The operational continuity is reassuring. The strategic uncertainty—whether commissioner-driven programs like the CNPV will maintain their pace—remains unresolved, and Revolution’s filing timeline depends on the answer.
4. ASCO Day 1 Confirms This Is the Most Data-Rich Oncology Meeting in Years
More than 40,000 attendees. More than 7,000 abstracts. Three plenary presentations. ADC combination data (sac-TMT plus Keytruda, 65% PFS reduction). Bispecific antibody survival data (ivonescimab). RAS inhibitor full Phase 3 data (daraxonrasib). Radiopharmaceutical updates. Cell therapy real-world evidence. The density of commercially significant data at this year’s ASCO exceeds any recent meeting. We begin full daily coverage with Monday’s plenary report.
Frequently Asked Questions
When is the ASCO plenary?
Tomorrow, Saturday May 31. Three presentations: Revolution Medicines RASolute 302 (pancreatic cancer, Brian Wolpin presenting), Akeso ivonescimab HARMONi-6 OS (squamous NSCLC), and J&J Erleada PROTEUS (high-risk prostate cancer). We will cover the full results in Monday’s email.
What do we know about Revolution’s data?
Topline: 13.2 months median OS versus 6.7 months (HR 0.40, p<0.0001) in second-line pancreatic cancer. The plenary will add PFS data, subgroup analyses, mature survival curves, and detailed safety data. Truist projects Q3 approval under CNPV.
What is the Lantheus/Curium offer?
A take-private offer from PE-backed Curium Pharma valuing Lantheus at approximately $7 billion. Lantheus makes PyL (prostate cancer imaging) and DEFINITY (cardiac imaging). The combined company would be the largest independent radiopharmaceutical company in the world.
What is Decnupaz?
AbbVie’s pivekimab sunirine, approved May 28 for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare aggressive blood cancer. This is the second approved treatment for BPDCN.
What is BridgeBio’s BBP-418?
Oral ribitol for limb-girdle muscular dystrophy type 2I/R9. NDA accepted with Priority Review. If approved, it would be the first FDA-approved treatment for any form of limb-girdle muscular dystrophy. PDUFA expected late 2026 or early 2027.
How many people are at ASCO?
More than 40,000 attendees with more than 7,000 abstracts across every major tumor type and therapeutic modality.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Plenary Final Preview. We provide the session-by-session guide to tomorrow’s three plenary presentations—what each dataset needs to show to support a broad label, what the market expects, and how each result changes the competitive landscape in its indication. This is the last preview before the data drop.
Radiopharmaceutical M&A. We analyze why Curium’s $7B Lantheus offer signals PE capital entering nuclear medicine at scale, how the diagnostic-therapeutic integration model creates competitive advantages that are difficult to replicate, and what the deal would mean for the radiopharmaceutical landscape.
Rare Disease Roundup. We assess AbbVie’s Decnupaz BPDCN approval and BridgeBio’s BBP-418 Priority Review acceptance in the context of the broader rare disease M&A and regulatory landscape.
Plus: ASCO Day 1 abstract highlights, plenary session logistics, Revolution filing timeline assessment, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
